Clinical trials: Metastatic Uveal Melanoma
Melanoma Metastatic, Uveal Melanoma, Metastatic
A Phase 1-1b Study to Evaluate the Safety, Efficacy and Dosimetry of Study Drug A9-3408 in Subjects With Metastatic Melanoma
The goal of this trial is to see if this investigational drug is safe for adult patients with melanoma that has spread to other parts of the body or cannot be removed by surgery.
- Conditions
- Melanoma Metastatic, Uveal Melanoma, Metastatic, Mucosal Melanoma
- Trial name
- NCT07076550
- Testing
- [225Ac]Ac-A9-3408, [68Ga]Ga-A9T-3202
- Where
- 4 sites in Australia
- Volunteers
- 5 people
- Sponsor
- Alpha-9 Oncology USA Inc.
Uveal Melanoma, Metastatic
Low Dose Dexamethasone for the Prevention of Cytokine Release Syndrome Associated With Tebentafusp
The goal of this clinical trial is to learn if a low dose of dexamethasone can prevent cytokine release syndrome in participants treated with tebentafusp for advanced uveal melanoma.
- Trial name
- LODEXA (NCT07803562)
- Testing
- Dexamethasone
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- University of California, San Diego
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma
The purpose of this study is to evaluate the safety and activity of BPX-701 in participants with relapsed AML, previously treated MDS, or metastatic uveal melanoma expressing high levels of PReferentially expressed Antigen in…
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndrome, Uveal Melanoma
- Trial name
- NCT02743611
- Testing
- BPX-701, Rimiducid
- Where
- 3 sites in United States
- Volunteers
- 4 people
- Sponsor
- Bellicum Pharmaceuticals
Metastatic Uveal Melanoma
Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma
This research study is investigating Binimetinib and Belinostat in participants with metastatic uveal melanoma. The research study will test the study drugs to see if the combination of binimetinib and belinostat can make tumors…
- Trial name
- NCT05170334
- Testing
- Binimetinib, Belinostat
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Ciliary Body and Choroid Melanoma, Medium/Large Size, Extraocular Extension Melanoma
Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic Melanoma
This phase II trial is studying how well giving bortezomib together with paclitaxel and carboplatin works in treating patients with metastatic melanoma.
- Conditions
- Ciliary Body and Choroid Melanoma, Medium/Large Size, Extraocular Extension Melanoma, Iris Melanoma, Recurrent Intraocular Melanoma
- Trial name
- NCT00288041
- Testing
- carboplatin, paclitaxel, bortezomib
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute (NCI)
Uveal Melanoma
Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the Liver
This study seeks to better understand the liver's immune response to receiving chemotherapy agent melphalan through Percutaneous Hepatic Perfusion (PHP) alone or in combination with Ipilimumab and Nivolumab for patients with…
- Trial name
- NCT07364474
- Testing
- Melphalan through Percutaneous Hepatic Perfusion, Melphalan through Percutaneous Hepatic Perfusion in combination with Ipilimumab and Nivolumab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Massachusetts General Hospital
Triple Negative Breast Cancer, Diffuse Large B Cell Lymphoma
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
A phase 1, multicenter, open label, non-randomized dose escalation and dose expansion study to examine the maximum tolerated dose, (MTD), minimum effective dose (MED) and/or recommended dose for expansion (RDE) of intratumoral…
- Conditions
- Triple Negative Breast Cancer, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Lymphoma, Non-Hodgkin
- Trial name
- ON-5001 (NCT06022029)
- Testing
- ONM-501, Cemiplimab
- Where
- 16 sites in United States, Australia
- Volunteers
- 168 people
- Sponsor
- OncoNano Medicine, Inc.
Uveal Melanoma, Melanoma
A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiated Liposarcoma, or Angiosarcoma
This is an open label study evaluating lifileucel (LN-144) in patients with metastatic uveal melanoma.
- Conditions
- Uveal Melanoma, Melanoma, Metastatic Uveal Melanoma, Metastatic Melanoma
- Trial name
- NCT05607095
- Testing
- Lifileucel (LN-144/LN-145)
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Brain and Central Nervous System Tumors, Intraocular Melanoma
Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Conditions
- Brain and Central Nervous System Tumors, Intraocular Melanoma, Lung Cancer, Melanoma (Skin)
- Trial name
- NCT00003022
- Testing
- iodine I 131 monoclonal antibody 3F8
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Metastatic Uveal Melanoma
Tebentafusp-tebn With LDT in Metastatic UM
This study is a multicenter, open label phase I/ II trial to assess the safety and clinical efficacy of tebentafusp-tebn in combination with liver-directed therapies in HLA-A*0201 positive patients with metastatic uveal melanoma.
- Trial name
- NCT06626516
- Testing
- Tebentafusp-Tebn, GM-CSF (Sargramostim), BCNU
- Where
- United States
- Volunteers
- 109 people
- Sponsor
- Thomas Jefferson University
Uveal Melanoma
Study Multicentre Evaluating the Effectiveness and Toxicity Sorafenib (Nexavar®) in Adult Patients With Uveal Melanoma and Metastatic Dissemination
The objective of the study is to determine the efficacy and toxicity of sorafenib in metastatic uveal melanoma. The main objective is to determine the non-tumor progression rate 24 weeks after initiation of treatment with…
- Trial name
- O-Mel-Sora (NCT02517736)
- Testing
- Sorafenib at a dose of 800 mg / day
- Where
- France
- Volunteers
- 32 people
- Sponsor
- University Hospital, Caen
Uveal Melanoma
Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma
Tumor Treating Fields targeted to liver metastases may improve outcomes for patients with metastatic uveal melanoma treated with immune checkpoint inhibitors.
- Trial name
- NCT05004025
- Testing
- Novocure Optune, Opdivo, Yervoy
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- HonorHealth Research Institute
Metastatic Uveal Melanoma
Defactinib and VS-6766 for the Treatment of Patients With Metastatic Uveal Melanoma
This phase II trial studies the effect of combining defactinib and VS-6766 in treating patients with uveal melanoma that has spread to other places in the body (metastatic).
- Trial name
- NCT04720417
- Testing
- Defactinib Hydrochloride, Raf/MEK Inhibitor VS-6766, Biopsy
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Thomas Jefferson University
Uveal Melanoma
A Cohort IND Expanded Access Program for Supporting Patient Access to Tebentafusp
This Expanded Access Program aims to: 1. Provide access to tebentafusp for mUM patients. 2. Provide access to tebentafusp for patients, who were on the control arm of the randomized controlled Phase II trial (IMCgp100-202) and…
- Trial name
- Non Applicable (NCT04960891)
- Testing
- Tebentafusp
- Sponsor
- Immunocore Ltd
Extraocular Extension Melanoma, Metastatic Intraocular Melanoma
Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery
This phase II trial studies how well axitinib works in treating patients with melanoma that has spread to other places in the body or cannot be removed by surgery.
- Conditions
- Extraocular Extension Melanoma, Metastatic Intraocular Melanoma, Recurrent Intraocular Melanoma, Recurrent Melanoma
- Trial name
- NCT01533948
- Testing
- axitinib, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Roswell Park Cancer Institute
Uveal Melanoma, Metastatic Cancer
Durvalumab (MEDI4736) Plus Cediranib in Patients With Metastatic Uveal Melanoma
Phase II clinical trial aimed to evaluate the efficacy of the combination of cediranib and durvalumab in patients with metastatic uveal melanoma (mUM) with biopsiable disease at first line of after failure to first line systemic…
- Trial name
- CEDUVEAL-M (NCT04184518)
- Testing
- Cediranib Maleate, Durvalumab
- Where
- 5 sites in Spain
- Sponsor
- Grupo Español Multidisciplinar de Melanoma
Acral Lentiginous Malignant Melanoma, Ciliary Body and Choroid Melanoma, Medium/Large Size
AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma
This phase II trial is studying how well AZD2171 works in treating patients with recurrent or stage IV melanoma. AZD2171 may stop the growth of tumor cells by blocking blood flow to the tumor and by blocking some of the enzymes…
- Conditions
- Acral Lentiginous Malignant Melanoma, Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size, Extraocular Extension Melanoma
- Trial name
- NCT00243061
- Testing
- cediranib maleate
- Where
- Canada
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma, Radiotherapy
Melanoma Inhibitory Activity (MIA): A Serological Marker for Metastatic Uveal Melanoma
Uveal Melanoma is the most common primary intraocular tumor in adults. Most tumors metastasize to the liver. So far no sensitive or specific serological tumor marker is routinely used.
- Conditions
- Melanoma, Radiotherapy, Metastatic Disease
- Trial name
- NCT00406900
- Testing
- Treatment of metastatic disease
- Where
- Germany
- Volunteers
- 560 people
- Sponsor
- Ludwig-Maximilians - University of Munich
Metastatic Malignant Solid Neoplasm, Metastatic Melanoma
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
This phase I trial studies the side effects and best dose of modified immune cells (IL13Ralpha2 CAR T cells) after a chemotherapy conditioning regimen for the treatment of patients with stage IIIC or IV melanoma or solid tumors…
- Conditions
- Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8
- Trial name
- NCT04119024
- Testing
- Biopsy, Biospecimen Collection, Computed Tomography
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- Anusha Kalbasi
Uveal Melanoma
Comparison Between Fotemustin to Intensive Surveillance in Patients With High Risk Uveal Melanoma
After the local treatment of the primary tumor (protonbeam-therapy, enucleation, external radiotherapy) patients with high risk of metastasis are randomized between: Adjuvant chemotherapy with Fotemustin.
- Trial name
- FOTEADJ (NCT02843386)
- Testing
- Adjuvant chemotherapy by Fotemustin, Intensive surveillance
- Where
- 6 sites in France, Switzerland
- Volunteers
- 302 people
- Sponsor
- Institut Curie